Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as a stand-alone treatment for patients who've failed other chemotherapy and for use in tandem with Roche's XelodaÂ in patients whose cancer has spread. A treatment course of Ixempra is expected to cost $18,000 to $23,000.
BMS pays $505M for Adnexus. Report
Better times ahead for BMS? Report
Cornelius get big payday for BMS temp job. Report
Read more on: Bristol-Myers Squibb